Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RG1671 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | EXPERIMENTAL | - |
| 6 | EXPERIMENTAL | - |
| 7 | EXPERIMENTAL | - |
| 8 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RG1671 | DRUG | Administered iv at escalating doses (with a starting dose of 0.0015mg) |
Inclusion Criteria: * adult patients, 18-50 years of age; * mild, intermittent, asymptomatic asthma; * history of asthma for \>=6 months; * non-smokers. Exclusion Criteria: * females of childbearing potential, or lactating; * history of immunologically medicated disease; * systemic antineoplastic...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
RG1671 is an investigational small molecule being developed for the treatment of asthma. It is currently in clinical development, with a Phase 1 study completed in patients with mild intermittent asymptomatic asthma. The drug is not yet approved and remains under investigation for this respiratory condition.
RG1671 is being developed by Roche Holding AG, a multinational pharmaceutical company. Roche's stock is traded under the ticker symbol RHHBY. The company is conducting clinical trials to evaluate the safety and efficacy of RG1671 in patients with asthma.
RG1671 is in Phase 1 of clinical development. A Phase 1 single ascending dose study has been completed in patients with mild intermittent asymptomatic asthma. The drug is still in the early stages of clinical testing and has not been approved by regulatory authorities.
RG1671 has one completed clinical trial, identified as NCT00517816. This was a Phase 1 single ascending dose study conducted in the United States, enrolling 43 patients with mild intermittent asymptomatic asthma. The trial was randomized, double-blind, and controlled, with participants aged 18 years and older.
RG1671 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for asthma. The completed Phase 1 trial was designed to assess safety and tolerability, but the drug has not yet received regulatory approval for any use.